Pharmacological management of fragile X syndrome: a systematic review and narrative summary of the current evidence

CONCLUSION: Based on this review to date there is limited data to support any specific pharmacological treatments, although the data for cannabinoids is encouraging in those with FXS and in future developments in gene therapy may provide the answer to the search for precision medicine. Treatment must be person-centered and consider the combination of medical, genetic, cognitive and emotional challenges.PMID:38393835 | DOI:10.1080/14656566.2024.2323605
Source: Expert Opinion on Pharmacotherapy - Category: Drugs & Pharmacology Authors: Source Type: research